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Abstract 
 
Introduction 
Dementia is a growing epidemic  affecting more than 45 million people worldwide, where Alzheimer’s 
disease (AD) accounts for approximately 60% of all cases of diagnosed dementia [1].  AD is incurable and 
progressive and the symptoms of AD are loss of memory and other cognitive skills, as well as loss of ability 
to perform activities of daily living [2]. The pathological hallmarks of AD are the extracellular accumulation 
of the protein amyloid beta (A ) in plaques as well as the protein tau that accumulates inside the neurons as 
neurofibrillary tangles. Both deposits  spread throughout the brain as the disease progresses [3].  
The effect of pharmacological treatments has so far been limited, with no new drugs approved in the last 
decade [4]. Therefore there is a crucial need to investigate non-pharmacological treatment opportunities.  
From animal studies we know that physical activity can improve cognitive performance [5] and even reduce 
the deposition of A  in the brain [6–8], and previous human longitudinal cohort studies have established a 
connection between physical exercise and reduced risk of AD [9,10]. One non-pharmacological approach to 
reduce A  in the human brain could therefore be to increase physical activity.  
The 42 amino acid-long aggregation-prone A  protein (A42) is derived from amyloid precursor protein 
(APP), which is a type I transmembrane protein expressed in the cell membrane of neurons and several other 
cell types, by proteolytic processing involving - and -secretase. This processing pathway is sometimes 
referred to as “the amyloidogenic pathway”, which may be regarded a misnomer since it also gives rise to 
soluble 17-40 amino acid long A forms, along with -cleaved soluble APP (sAPP), all of which are 
secreted from the cell. APP can also undergo non-amyloidogenic processing by -secretase, which results in 
the release of sAPP, and by - and -secretase, which results in the release of 13-16 amino acid-long, 
soluble A species that do not form plaques. (ref: Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, 
Blennow K. Neurodegener Dis. 2012;10(1-4):138-40) 
The stoichiometry of sAPP   and   have not been established, however it is speculated that it is generated 
in as 1:1 manner [14].  
A potential mechanism for the treatment of AD could be a reduction in A  plaque formation by modulating 
the APP processing by   ,    and  -secretases. We speculated that physical exercise could be such a 
modulator. In a multicentre randomized controlled trial, the Preserving Cognition, Quality of Life, Physical 
Health and Functional Ability in Alzheimer’s Disease: The Effect of Physical Exercise (ADEX) study, we 
have recently established that physical exercise can alter the cognitive function and reduce neuropsychiatric 
symptoms in patient with mild AD [9, 10] [15]. However, the underlying molecular mechanisms are not 
known [16]. Our hypothesis was that moderate-to-high intensity physical exercise would increase sAPP 
and soluble A species and reduce CSF markers of  neurodegeneration (T-tau and P-tau) in patients with 
clinically diagnosed mild AD. 
 
Materials and methods 
Participating subjects 
Two-hundred community-dwelling patients with clinical diagnosed mild AD were included and randomized 
to either a control group with treatment as usual or a 16 week 60 min 3 times per week moderate-to-high 
intensity physical exercise group.  All subjects donated a blood sample before and after intervention, and 
were tested at baseline and at 16 week follow-up with a comprehensive battery of tests of cognitive function, 
Activities of Daily Function, Quality of Life, physical activity and neuropsychiatric symptoms. For details of 
inclusion and exclusion criteria and methods, please see [9]. A subgroup of 44 subjects recruited from 3 of 
the 8 centers had a lumbar puncture performed to collect CSF samples before and after intervention. For this 
sub-study, only subjects with biomarker-positive AD were included (A 42<550 pg/ml, positive PiB-PET 
amyloid binding) (n=?). 
Intervention 
The physical exercise intervention used in this study was a aerobic exercise consisting of three weekly 
sessions of 1hour duration in groups of 2-5 participants, supervised by an experienced physiotherapist. The 
first four weeks of exercise consisted of an adaption period, and the subsequently 12 weeks participants 
performed aerobic exercise of moderate-to-high intensity (in each session a total 3*10 minutes on an 
ergometer bicycle, cross trainer and treadmill with 2-5 min rest in between). Heart Rate (HR) was monitored 
during aerobic exercise, including the rest intervals. Target intensity was 70-80% of maximal HR (220-age).  
The participants assigned to the control group received treatment as usual.  
Statistics 
The baseline characteristics age, MMSE, weight, height and BMI, and the outcome measures at baseline, 
were compared between the two groups using independent t-tests. The difference between changes in 
outcomes from baseline to follow-up after 16 weeks of intervention between the groups, were analyzed in 
two independents analyses, an intention to treat (ITT) analysis where all participant were analyzed, and in a 
per protocol analysis (high exercise subjects), where only the subjects that exercised with a mean intensity of 
> 70% of maximal HR and attended >80% of the sessions were included. The significance level was set to 
0.05. 
Outcomes 
The primary outcome measures were group differences in changes from baseline in the CSF concentration of 
A  isoforms, tau, phosphorylated tau, and the two proteolytic isoforms of the A  precursor protein APP   
and  . Furthermore ApoE genotype for polymorphism 334 and 472 was included in analysis. 
Sample material 
CSF was collected from a total of 44subjects, before and after intervention. CSF was obtained by lumbar 
puncture in polypropylene tubes. After collection the CSF samples were centrifuged at 2000 g at 4C and 
aliquoted in to 250ul aliquots in cryotube, within 2 hours of collection, and frozen at -80C for later use as 
recommended [17].  
 
A Triplex 
CSF concentrations of A38, A40 and A42 were measured using V-plex Peptide Panel 1 Kits A 38, 
A 40, A 42 (Meso Scale Discovery system, Rockville, MD, USA) according to the manufacturer’s 
protocol. In brief, 60 ul of CSF was diluted 2-fold in diluent provided with the kit. Calibrators and controls 
were prepared according to protocol. On a capture antibody pre-coated 96 well MSD plate, 25 ul of sample, 
calibrator or controls were added, 25 ul of detection antibody, and incubated at room temperature for 2 
hours. The plate was then washed in washing buffer provided with the kit, and read in a MSD imager at 
appropriate wavelength.  
Total-tau 
CSF T-tau was measured by the hTAU Ag ELISA assay (INNOTEST, Fujirebio, Japan) according to the 
manufacturer’s protocol. On an anti-human tau antibody pre-coated 96 well microtiter plate, 25 ul samples, 
controls and standards ranging from 50-2500 pg/mL were added to the microtiter plate and incubated in each 
well with a biotinylated detection antibody to tau, followed by addition of peroxidase-conjugated 
streptavidin. The reaction was developed with tertamethyl benzidine (TMB) chromogen solution, and 
subsequently stopped with 0.9M sulfuric acid, and quantified at 450 nm in a microplate reader. 
Phosphorylated-tau 
CSF tau phosphorylated at amino acid 181 (p-tau) was measured by the PHOSPHO-TAU (181p) ELISA 
assay (INNOTEST, Fujirebio, Japan) according to manufacturer’s protocol. On an anti-human p- tau 
antibody pre-coated 96 wells microtiter plate, 75 ul samples, controls and standards ranging from 15.6-1000 
pg/mL were added to the microtiter plate and incubated in each well with a biotinylated detection antibody to 
p-tau, followed by addition of peroxidase-conjugated streptavidin. The reaction was developed with TMB 
chromogen solution, and subsequently stopped with 0.9M sulfuric acid, and quantified at 450 nm in a 
microplate reader. 
Immunoprecipitation mass spectrometry of A 
Immunoprecipitation mass spectrometry (IP-MS) of the full spectrum of A forms present in CSF was 
performed as previously described [18]. In brief, … Erik. 
A1-13/14/15/16 represent the non-amyloidogenic -/-processing pathway, whereas longer fragments 
represent - and -dependent pathways. A fragments ending at amino acid 42 are the only markers of 
plaque pathology, whereas all other A forms are soluble species.  
Soluble amyloid precursor protein   and   
sAPP and sAPP were measured using Human sAPP  and Human sAPP  kits, respectively (IBL, Japan) 
according to the manufacturer’s protocol. In brief, 100 ul of 1:40 diluted CSF, controls and standards 
(ranging from 0.78 to 50 ng/mL) were added to wells of anti-human sAPP  or sAPP  antibody pre-
coated microtiter plates and incubated over night at 4°C. Following incubation, 100 uL HRP-conjugated 
detection antibody was added to the wells. The reaction was developed with TMB chromogen solution, and 
subsequently stopped with 1M sulfuric acid, and quantified at 450 nm in a microplate reader. 
Apolipoprotein E genotyping 
APOE genotyping for the  2, 3,and 4 alleles was performed with a TaqMan qPCR assay as described by 
Koch et al., 2002 [19].  DNA was isolated with Promega Maxwell DNA purification kits (Promega, WI, 
USA), according to the manufacturer’s protocol from 250 uL of buffy coat from 6 mL EDTA vials.  
 
Results 
Baseline participating subjects 
From the 200 randomized subjects of the intervention study, CSF samples were obtained from 56 subjects by 
lumbar puncture in addition to blood samples from all participants. Of the 44 subjects with a CSF sample 
available 53 met criteria regarding A 42 below 550 pg/mL for those 3 with levels >450 pg/mL, a PiB-PET 
scan was analyzed. In all three cases, the PiB-PET scan was negative, and the patients were excluded. There 
were no significant difference in baseline characteristics between the intervention group and control group in 
any of the parameters (table 1). Of the 53 subjects, 18 were female (34.1 %), the mean age was 68.7 years 
and the mean MMSE score was 25.3. In the intervention group, 18 subjects (69.2%) exercised with an 
intensity of more than 70% of maximal HR during the sessions (high exercise subjects). There was no 
significant difference in the three groups at baseline (supplementary table 1). 
The baseline characteristics of the subjects with CSF samples are shown in table 1. 
 Controls (n=27) Intervention (n=26)  
 Mean (SD) Mean (SD) p-value 
Age, yeans 69.2 (3.89) 68.12 (6.76) 0.59 
Gender   0.06 (chi2) 
 Male, n (%) 21 (39.6) 14 (26.4)  
Female, n (%) 6 (11.3) 12 (22.6)  
Disease duration, years 1.5 (1.0) 1.08 (1.0) 0.13 
MMSE 25.1 (3.9) 25.5 (2.28) 0.62 
Characteristics    
Weight, kg 72.7 (13.7) 76.2 (16.1) 0.40 
Height, cm 175.7 (8.3) 173.4 (9.0) 0.33 
BMI 23.5 (3.7) 25.3 (4.4) 0.11 
ApoE e4   0.22 
0, n (%) 11 (20.8) 5 (9.4)  
1, n (%) 9 (17.0) 13 (24.5)  
2, n (%) 7 (13.2) 8 (15.1)  
Table 1: Subjects baseline characteristics. 
Baseline concentrations of AD biomarkers 
The concentration of A         , t-tau, p-tau and sAPP   and  , are shown in table 2. There was no 
statistical significant difference in baseline mean concentration of these markers when comparing controls 
and intervention groups, see table 2a and b. Furthermore, there was no difference in baseline ratios 
(A42/A40 or sAPP/sAPP) when comparing controls and intervention, see table 2a and b. Analysis of 
the relative expression of A  isoforms long/short ratio analyzed by IP-MS revealed no statistical significant 
difference at baseline (see table 2b).  
Intention to treat analysis 
Mean between-group difference in outcomes after 16 weeks of intervention are shown in table 2. There was 
no significant difference in changes from baseline to follow-up between the control and intervention groups 
in any of the outcome measures. Furthermore, changes in the Ab42/40 ratio were similar in controls and 
intervention group with a mean difference of 0.003 (95% CI: -0.0009;0.006). Similarly, no group difference 
was found for the sAPP /sAPP  ratio (mean difference of change 0.21 (-0.46;0.89). Analysis of the 
changes in relative expression of A  isoforms long/short ratio from baseline to follow-up between the 
groups was 0.35 (-0.88;1.59) and was not statistically significant. Figure 1 displays the difference in outcome 
measure form baseline to follow-up.   
Per protocol analysis 
Dividing the intervention group into low and high exercise subjects did not alter the results. At follow-up, the 
high exercise subjects (n=18) did not differ from the control group in any of the outcome measures (table 2 A 
and B).  
 
Discussion 
The current study investigated the effects of physical exercise on A  isoforms, cleaved APP subtypes, and 
the neuronal injury markers t-tau and p-tau. We found that there was no significant effect of physical 
exercise on any of the most important CSF AD biomarkers, either in a IIT analysis of all subjects, or in a per 
protocol analysis, where only subjects that adhered to the exercise program were included.  
A substantial limitation of the current study is the small sample size. Only 53 subjects were analyzed for 
levels of outcome markers in CSF. This low samples size might not generate enough power to statistically 
calculate a significant difference in mean levels. Another question to discuss is the duration of the exercise 
intervention. In a review from 2015 by our group, multiple exercise interventions in dementia or MCI 
patients where reviewed. The intervention ranged from a single burst of exercise to duration of 26 weeks, 
with various effects on biomarkers. In our study the intervention was of 16 weeks, which might not be long 
enough to see a significant alteration in A  and tau. Furthermore, there has been for logistic reasons a time 
lag from the last exercise session to the date of lumbar puncture. The effect of physical exercise could be 
transient or only be present when the individuals exercise regularly, the effect therefore might not been 
measurable in our samples. 
One of the strengths in our study is the good adherence to the study in general (96%) and a good per protocol 
adherence (69.2%) to the targeted exercise of over 70% of maximal HR. All exercise sessions have been 
supervised by professional and experienced trainers and the levels of activity have additionally been 
monitored by pulse watches. Furthermore, we have biological samples before and after the intervention. 
Our findings are in disagreement to previous studies in animal models for AD. Both A  and p-tau have been 
shown to be reduced in the brain as a response to moderate-intensity exercise in transgenic mice models for 
A  and tau respectively [6,20]. Our study is the first to investigate the effect of physical exercise on 
biomarkers of AD in a controlled setting. Therefore, evidence for an effect on AD pathology in humans is 
sparse. 
The amyloid mouse models that are used in Um et al., 2008[8] and Adlard et al., 2005[6] are transgenic 
models (Tg) overexpressing APP [21,22]. The overexpression of proteins in models raises some question 
concerning protein integrity, such as that over expression of proteins in itself could be toxic for the cells, and 
cell toxicity therefore is not protein specific. In addition, over expression generates vast amounts of protein 
that could enable a not representative large detectable reduction after intervention studies. Furthermore, the 
Tg NSE/APPsw mouse model used in Um et al., 2008  does not develop plaques, as seen in human patients 
with AD [23]. The above mentioned  could indicate that the pathology of A  in the mouse brain differs in 
such a great way from the human, that direct comparison of the effect of an exercise intervention can be 
problematic and could account for the disagreement between our findings and previous findings. 
There could be other explanations for the lack of significant changes in CSF measures of AD pathology. We 
assumed that decreased amyloid accumulation in the brain would be reflected in an increased clearance of 
A  from the brain to CSF. However the physical exercise may not lead to an increased clearance via the 
CSF, but to an increase in on-site clearance by proteases. Previous studies have found the enzymes Insulin 
degrading enzyme (IDE) and neprilysin might contribute to the clearance of A  [24,25]. A recent study 
found that exercise training reduced extracellular soluble A  in the brains of Tg2576 mice in a dose-
dependent manner through an up-regulation of A  clearance caused by an induction of IDE and neprilysin 
[26]. However, such a clearance should be reflected in the CSF by increased levels of A1-X (Erik, which 
A forms would you regard as the most established IDE and NEP products?).  
We analyzed whether physical exercise had the potential to shift towards the non amyloidogenic pathway of 
APP processing by analyzing the sAPP   and   forms and the ratio between sAPP / . We did not find a 
significant difference in the sAPP /  ratio in our study   sAPP  and   give rise to  isoforms of A  
shorter than 16 amino acids (aa) and longer than 16 aa, respectively [27,28]. We analyzed whether the ratio 
between long and short isoforms of A  was affected by physical exercise, by analyzing the relative 
expression of the A  isoforms that represent amyloiogenic ad non-amyloidogenic APP-processing, 
respectively. We found no significant difference in the mean ratios indicating that physical exercise does not 
seem to influence the cleavage of APP towards the non- amyloidogenic pathways. Further, there was no 
relative increase in C-terminally truncated A isoforms, e.g., A1-37 and A1-38, that are thought to be 
markers of beneficial -secretase modulation.   
Drug trials have also addressed A  as a target for AD pathology. Lately there have been trials with antibody 
treatment and immunizations against A  to prevent plaque formation. However, without overwhelmingly 
positive results [29]. A new target in preventing A  plaque formation is the prevention of production of the 
isoforms of A  that are prone to aggregate 
Another matter to consider is that the subjects in this study and in previous studies are already diagnosed 
with AD. An intervention to reduce amyloid plaque formation might be more effective several years before 
the fulfillment of criteria for dementia, since A  plaque formation precedes these criteria. In a study by 
Baker et al., 2010 [30], there was a trend that physical exercise could alter the levels of A  in plasma in 
mild cognitive impaired (MCI) subjects, although this finding was not significant.  
In conclusion, the molecular mechanism behind the cognitive effect of a 16-week exercise intervention could 
not be explained by modulation of A  or Tau levels in the CSF of patients with AD. More studies 
investigating other likely pathways are to be performed.   
 
 
 
 
 
 
 
Table 2 
A 
Baseline 16 week follow-up Between group difference in mean change from baseline 
Control (n=25) Intervention 
(n=26) 
 Control (n=20) Intervention 
(n=22) 
Intervention versus control High exercise  (n=16) versus 
control 
 
Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD)   (95%CI) p-value   (95%CI) p-value 
-amyloid 38 1754 (616) 1947 (727) 0.27 2034 (991) 1934 (627) 44.4 (-157.7;246.5) 0.69 114.5 (-111.2;340.2) 0.31 
-amyloid 40 3720 (1221) 4148 (1319) 0.24 4549 (1802) 4187 (1158) 336.3 (-135.1;807.8) 0.16 410.5 (-119.8;940.7) 0.12 
-amyloid 42 144 (68) 175 (107) 0.23 195 (80) 200 (121) 19.8 (-12.79;52.4) 0.23 27.1 (-7.69;61.94) 0.12 
-amyloid 42/40 ratio 0.038 (0.012) 0.041 (0.021) 0.52 0.044 (0.013) 0.046 (0.022) 0.003 (-0.0009;0.006) 0.14 0.003 (-0.0008;0.007) 0.11 
Total-tau 692 (373) 721 (385) 0.79 639 (136) 664 (141) -53.1 (-291.3;185:0) 0.65 -87.4 (-369.7;194.8) 0.52 
Phosphorylated-tau 72 (30) 82 (31) 0.23 32 (6.9) 35 (7.3) 5.6 (-3.011;14.30) 0.19 4.8 (-3.62;13.22) 0.25 
 
B 
Baseline 16 week follow-up Between group difference in mean change from baseline 
Control (n=22) Intervention 
(n=23) 
 Control (n=19) Intervention 
(n=20) 
Intervention versus control High exercise  (n=14) versus 
control 
 
Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD)   (95%CI) p-value   (95%CI) p-value 
sAPP 362 (239) 412 (198) 0.45 289 (66) 151 (33) 55.5 (-71.23;182.2) 0.38 66.6 (-78.01;211.3) 0.35 
sAPP  859 (726) 942 (444) 0.64 409 (94) 422 (94) 69.1 (-141.7;279.9) 0.51 27.6 (-196.9;252.1) 0.80 
sAPP / ration 2.14 (0.41) 2.38 (0.71) 0.52 2.29 (0.92) 2.26 (0.53) 0.21 (-0.46;0.89) 0.52 0.03 (-0.65;0.33) 0.92 
Table 2. Changes in CSF AD biomarkers after 16 weeks of intervention. A: Values for  -amyloid, tau and phosphorylated -tau. B: Measures of amyloid precursor 
protein isoforms   and  , and the ration between the isoforms.  
 
 
Table 3 
Baseline 16 week follow-up Between group difference in mean change from baseline 
Control (n=24) Intervention 
(n=26) 
 Control (n=21) Intervention 
(n=23) 
Intervention versus control High exercise  (n=13) versus 
control 
 
Mean (SD) Mean (SD) p-value Mean (SD) Mean (SD)   (95%CI) p-value   (95%CI) p-value 
-amyloid long/short 6.57 (1.99) 6.65 (2.26) 0.90 8.60 (7.97) 6.84 (2.69) 0.35 (-0.88;1.59) 0.57 0.28 (-1.02;1.58) 0.66 
Table 3. Ration between relative expressions of long versus short forms of -amyloid. Long isoforms of A  >17 amino acids, short isoforms of A <16 amino acids 
 
 
Figure 1. Scatterplot of changed from baseline to 16 weeks follow-up in outcome measure. Controls are in red, the 
exercise group in blue. The open dots in the exercise group belong to the low exercise group (HR<70% of maximal HR, 
see supplementary table 1). A)  -amyloid 1-38, B)  -amyloid 1-40, C)  -amyloid 1-42, D)  -amyloid 42/40 ration, E) 
total- tau, F) phosphorylated-tau, G) sAPP  , H) sAPP  , I) sAPP /  and J)  -amyloid long/short isoforms. 
 
Supplementary 
Supplementary table 1 
 Controls (n=27) Low exercise (n=8) High exercise (n=18)  
 Mean (SD) Mean (SD) Mean (SD) p-value 
Age, yeans 69.2 (3.9) 66.8 (4.3) 68.72 (7.6)  
Gender    0.18 
 Male, n (%) 21 (39.6) 4 (7.5) 10 (18.9)  
Female, n (%) 6 (11.3) 4 (7.5) 8 (18.9)  
Disease duration, years 1.5 (1.0) 0.88 (0.99) 1.17 (0.99) 0.25 
MMSE 25.1 (3.9) 26.8 (2.8) 25.0 (2.6) 0.42 
Characteristics     
Weight, kg 72.7 (13.7) 77.8 (14.9) 75.6 (17.0) 0.66 
Height, cm 175.7 (8.3) 173.6 (9.1) 173.3 (8.6) 0.63 
BMI 23.5 (3.7) 25.9 (5.0) 25.0 (4.2) 0.25 
ApoE e4    0.23 
0, n (%) 11 (20.8) 3 (5.7) 2 (3.8)  
1, n (%) 9 (17.0) 4 (7.5) 9 (17.0)  
2, n (%) 7 (13.2) 1 (1.9) 7 (13.2)  
Supplementary table 1: Subjects baseline characteristics controls, low exercise and high exercise. 
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